首页工具

登录

搜索结果

Search Results for " self-administration "

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。 QQ咨询网站留言咨询

Cat. No.	Product Name	Target	Signaling Pathways
T8959	OS-3-106	Dopamine Receptor	GPCR/G Protein; Neuroscience
	OS-3-106 是一种新型芳酰胺苯基哌嗪，在腺苷酸环化酶抑制试验中作为 D3R 的部分激动剂。
T22976	MFZ 10-7	Others; GluR	Neuroscience; Others
	MFZ 10-7 是 mGluR5 的负变构调节剂。
T15799	LY2940094 LY-2940094	Opioid Receptor	Endocrinology/Hormones; GPCR/G Protein; Neuroscience
	LY2940094 (LY-2940094) 是一种口服有效的选择性 NOP 受体拮抗剂，可降低动物模型的自身给药酒精依赖，对 NOP 受体具有高亲和力，Ki 为 0.105 nM，和拮抗活力，Kb 为 0.166 nM。
T39161	Ro60-0175 Ro60-0175	5-HT Receptor	GPCR/G Protein; Neuroscience
	Ro60-0175 是 5- 羟色胺 2B (5-HT2B) 和 5- 羟色胺 2C (5-HT2C) 血清素受体亚型的选择性激动剂，常用富马酸盐形式。它具有 5- 羟色胺 2B 受体激动剂和 5- 羟色胺 2C 受体激动剂的作用。
T36520	COR659	Cannabinoid Receptor; GABA Receptor	GPCR/G Protein; Membrane transporter/Ion channel; Neuroscience
	COR659 是一种有效的 GABAB 的阳性变构调节剂。COR659具有缓解大鼠对酒精和巧克力成瘾的作用。
T79909	AEF0117	Cannabinoid Receptor	GPCR/G Protein
	AEF0117为一种针对大麻素受体1 (CB1-SSi) 的信号传导特异性抑制剂，抑制大麻素自我给药和与四氢大麻酚相关的行为障碍，可用于研究大麻戒断。
T37610	AT-121	Opioid Receptor	Endocrinology/Hormones; GPCR/G Protein; Neuroscience
	AT-121 是一种双重μ-阿片和神经肽受体部分激动剂（Kis 分别为 16.49 和 3.67 nM）。它能刺激[35S]GTPγS 与表达μ-阿片受体或神经肽受体的细胞膜结合（EC50s 分别为 19.6 和 34.7 nM）。AT-121（0.003-0.03 mg/kg）能以剂量依赖的方式降低辣椒素诱导的热异感，但不会增加恒河猴的搔抓活动。在恒河猴药物自我给药试验中，AT-121 每次注射剂量为 0.3 至 10 μg/kg，它缺乏强化作用（一种潜在的滥用标志），不能减少食物颗粒的强化作用。AT-121（0.01 或 0.03 毫克/千克）不会诱发恒河猴的超痛觉，超痛觉是产生耐受性的标志。AT-121 是一种安全、无成瘾性的缓解疼痛药，具有抗伤害和止痛作用。
T71262	AZD-8418
	AZD-8418 is an mGlu2 receptor positive allosteric modulators that attenuates nicotine-taking and nicotine-seeking behavior. Acute treatment with AZD8418 (0.37, 1.12, 3.73, 7.46, and 14.92 mg/kg) and AZD8529 (1.75, 5.83, 17.5, and 58.3 mg/kg) deceased nicotine self-administration and had no effect on food-maintained responding. Chronic treatment with AZD8418 attenuated nicotine self-administration, but tolerance to this effect developed quickly. The inhibition of nicotine self-administration by c...
T26791	BHF-177
	BHF-177 is a positive allosteric modulator of the GABAB receptor. BHF-177 reduces self-administration of nicotine in animal studies.
T35546	Yhhu 3792
	Notch signaling pathway activator; enhances the self-renewal capability of neural stem cells (NSCs) via Notch signaling pathway activation in vitro and in vivo. Promotes the expression of Notch target genes, Hes3 and Hes5. Expands the NSCs pool and promotes endogenous neurogenesis in the hippocampal dentate gyrus (DG) after chronic administration in mice. Increases the spatial and episodic memory in mice.
T37202	CC4 CC4
	High affinity and subtype selective α6β2 and α4β2 partial agonist (Ki values are 12 and 26nM for rat α6β2 and α4β2 receptors respectively). Has low affinity for α3β4 and α7 receptors (Ki values are 4.8 and 13 μM for human α3β4 and rat α7 receptors respectively). Stimulates dopamine release from striatal slices in vitro. Attenuates nicotine-induced self-administration and conditional place preference in rats. Sala et al (2013) CC4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 ...
T70987	AT-1001
	AT-1001 is an α3β4 nAChR partial agonist. AT-1001 attenuates stress-induced reinstatement of nicotine seeking in a rat model of relapse and induces minimal withdrawal in dependent rats. AT-1001 also potently and reversibly blocks epibatidine-induced inward currents in HEK cells transfected with α3β4 nAChR. Importantly, AT-1001 potently and dose-dependently blocks nicotine self-administration in rats, without affecting food responding. When tested in a nucleus accumbens (NAcs) synaptosomal prepar...
T36929	Pal-KTTKS (acetate)
	Pal-KTTKS is a lipidated pentapeptide consisting of a fragment of the type I collagen C-terminal propeptide conjugated to palmitic acid .1 It increases collagen production in human corneal and dermal fibroblasts when used at concentrations of 0.002, 0.004, and 0.008 wt%.2 Following topical administration, pal-KTTKS (50 μg/cm2) is found in the stratum corneum, epidermis, and dermis of isolated hairless mouse skin.1 It can self-assemble into flat tapes and extended fibrillar structures.3 Pal-KTTKS...
T83776	Dopamine D3 Receptor Agonist 13a
	Dopamine D3 受体激动剂13a是一种Dopamine D3 受体激动剂。该化合物选择性地与Dopamine D3 受体结合，相较于Dopamine D1、D2和D4受体(Kis = 0.14、4,600、2.85和756 nM，分别)具有更高的亲和力，并且还能与血清素(5-HT)受体亚型5-HT1A、5-HT2A、5-HT2B和5-HT2C(Kis = 6、54、1.47和252 nM，分别)结合；然而，它是Dopamine D2受体的部分激动剂(EC50 = 2.26 nM，在G蛋白招募分析中)并且作为Dopamine D3受体的拮抗剂(IC50 = 4.62 nM)。在大鼠身上，当剂量为3 mg/kg时，Dopamine D3 受体激动剂13a能减少可卡因自我给药。

化合物

Cat.No: T8959

Target: Dopamine Receptor

Cat.No: T22976

Target: Others, GluR

Cat.No: T15799

Synonym: LY-2940094

Target: Opioid Receptor

Cat.No: T39161

Synonym: Ro60-0175

Target: 5-HT Receptor

Cat.No: T36520

Target: Cannabinoid Receptor, GABA Receptor

Cat.No: T79909

Target: Cannabinoid Receptor

Cat.No: T37610

Target: Opioid Receptor

Cat.No: T71262

Cat.No: T26791

Cat.No: T35546

Cat.No: T37202

Synonym: CC4

Cat.No: T70987

Pal-KTTKS (acetate)

Cat.No: T36929

Dopamine D3 Receptor Agonist 13a

Cat.No: T83776

我们的所有产品和服务仅用于科学研究，不能被用于人体，我们也不向个人提供产品和服务。

Copyright © 2015-2024 TargetMol Chemicals Inc. All rights reserved. 沪ICP备20019793号-4

沪公网安备 31010602006700号

沪公网安备 31010602006700号

TargetMol Loading

联系我们

电话：

400-820-0310

邮箱：

service@tsbiochem.com

QQ：

2881945090（终端用户）

2885109491（经销商）

经销：

终端：

地址：

上海市静安区江场三路238号8楼